FibroGen will report Q2 2026 results after market close, with consensus EPS at -$3.18 and revenue of $2.01M.
FibroGen (KYNB) will announce its Q2 2026 earnings on August 13 after the market closes. Analysts expect a loss of $3.18 per share and revenue of $2.01 million, reflecting a 48.9% year-over-year increase.
Over the past three months, EPS estimates have seen one upward and one downward revision. Revenue estimates have followed a similar pattern, with one upward and one downward adjustment. The company’s financial performance will be closely watched amid recent volatility in biotech earnings.
No immediate market reaction details were provided ahead of the release.